Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine Notice of the commencement of sales of “ReproCryo DMSO free”
- Company: REPROCELL,Inc. (JASDAQ Company code: 4978)
- Representative: Chikafumi Yokoyama, PhD
- Contact: info-us@reprocell.com
We hereby wish to inform you that, on August 20th 2015, in conjunction with the Institute for Frontier Medical Sciences, Kyoto University, REPROCELL announced to the press the release of “ReproCryo DMSO free”, our high-performance cryopreservation solution for human ES/iPS cells required in regenerative medicine, and start to commence sales of the product.
In regenerative medicine, the long-term freeze-preservation and banking of large quantities of human ES/iPS cells is an essential process. REPROCELL has succeeded in developing “ReproCryo DMSO free”, a new cryopreservation solution that is optimal for use in regenerative medicine. This cryopreservation solution consists solely of components scientifically proven to be highly safe, thus delivering a high degree of safety within the field of regenerative medicine. “ReproCryo DMSO free” also allows for the simultaneous freezing of a large quantity of cells, thus making the product suitable for automated processing. This technology represents a major contribution to the realization of regenerative medicine, which utilizes human ES/iPS cells.
The product was jointly developed with the Institute for Frontier Medical Sciences, Kyoto University in a development project for Japan Agency for Medical Research and Development (AMED), the national research and development corporation which was inaugurated in April this year.
Taking advantage of our strengths in global-scale advanced research networks and the superior technology of the ES/iPS cells we have cultivated thus far, our company group is advancing initiatives in the field of regenerative medicine. “ReproCryo DMSO free” holds an extremely important position as a product working for the promotion of regenerative medicine and is expected to make a significant contribution to the expansion of our group’s business.
For more information, visit: https://www.reprocell.com/